In brief
- The 2026 European Drug Report from the EU Drugs Agency (EUDA) finds that harm reduction has expanded across Europe, though with stark differences between countries.
- Drug checking services exist in only 11 of the 29 countries studied—one fewer than the previous year—despite being a highly requested tool at festivals.
- Spain stands out positively: it offers syringe exchange programs in all its prisons and is one of five nations that distributes injectable naloxone according to WHO standards.
On June 9, the European Union Drugs Agency (EUDA, formerly the EMCDDA) presented the 2026 European Drug Report, its annual snapshot of consumption, markets, and health responses across 29 countries: the 27 EU member states plus Norway and Turkey. Among its chapters, the section dedicated to harm reduction reviews the status of supervised consumption rooms, opioid agonist treatments, and naloxone programs in Europe using 2024 and 2025 data, though actual access to these services depends heavily on one’s country of residence.
Consumption rooms and naloxone: Uneven expansion
The report counts 100 supervised consumption rooms operating in 13 EU countries plus Norway during 2025—spaces where users can inject or smoke substances under medical supervision. The EUDA notes that available data suggests these spaces help reduce substance-related deaths, though it acknowledges that evaluation remains complex and the evidence base is still developing. Naloxone, the antidote that reverses opioid overdoses, is available in 19 European countries; Spain is among the five nations that use the 0.4 mg/ml injectable vial recommended by the World Health Organization. It shares with Luxembourg the distinction of offering syringe exchange in all of its correctional facilities, a feat that neither France (limited to ten prisons) nor Germany (only one, for women) has yet managed to match. Regarding methadone or buprenorphine treatment for opioid dependence, 14 of the 22 countries with available data are already meeting the coverage targets set by the WHO.
The weak point: Drug checking services
The most striking figure from a harm reduction perspective is that of drug checking services—those fixed or mobile points at festivals where anyone can bring a pill or sample to find out what it actually contains before consuming it. According to the report, only 11 of the 29 countries had this service in 2025, one fewer than in the previous edition. This figure contrasts with the growing demand among those attending parties and festivals, and with the accumulated evidence that substance analysis reduces intoxications by detecting adulterants or unexpectedly high doses—something especially relevant for those who use MDMA or LSD in recreational contexts.
What this means
The report makes no moral judgments about consumption; it describes health services and their coverage, data point by data point. The significance for the psychonaut community is twofold. On one hand, it confirms that harm reduction now enjoys solid institutional recognition in the EU, with funding and ongoing evaluation. On the other, it makes clear that this recognition does not automatically translate into more resources where they are needed most: the stagnation of drug checking, precisely the service most linked to the recreational use of psychedelics and MDMA, suggests that political resistance persists even in countries advancing on other fronts, such as the Czech Republic, which has just legalized medical psilocybin. It is worth remembering that these data correspond to 2024 and 2025, and that the country-by-country picture may have already changed in some specific areas since then.
Source
- Lasdrogas.info (Fundación Atenea). The EUDA confirms progress in harm reduction but points out major differences between European countries, based on the 2026 European Drug Report from the EU Drugs Agency (EUDA), July 14, 2026.
- EUDA. European Drug Report 2026: Trends and Developments, presented June 9, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
